A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia-Reference-Cited by-同舟云学术

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Published:2014-05-08 Issue:19 Volume:370 Page:1809-1819
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Blom Dirk J.,Hala Tomas,Bolognese Michael,Lillestol Michael J.,Toth Phillip D.,Burgess Lesley,Ceska Richard,Roth Eli,Koren Michael J.,Ballantyne Christie M.,Monsalvo Maria Laura,Tsirtsonis Kate,Kim Jae B.,Scott Rob,Wasserman Scott M.,Stein Evan A.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1316222

Cited by 612 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN study;American Heart Journal;2024-11

2. Targeting the MHC-I endosomal-lysosomal trafficking pathway in cancer: From mechanism to immunotherapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease;JAMA Cardiology;2024-09-01

4. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond;American Journal of Preventive Cardiology;2024-09

5. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes;Journal of Clinical Medicine;2024-08-25